Results
The results of the study are given in Table I- 
Discussion
In our study, we observed the effects of glimepiride and pioglitazone on the hs-CRP level, glycemic and lipidemic status of the type 2 diabetic patient. For this purpose, we enrolled 70 type 2 diabetic patients. Among them 35 were treated with pioglitazone 30mg in the morning for 12 weeks of time and rest 35 type-2 diabetic patients were treated with glimepiride (1 to 6 mg, according to the glycemic status) for the same time.
In this study the control of glycemic status was suboptimal in both group with the drug intervention, i.e. mean HbA1c% was reduced 8.79% to7.94% in pioglitazone group and 7.29% to 7.03% in glimepiride group. Reduction of mean fasting blood sugar in pioglitazone group was 9.86mmol/L to 8.26mmol/L, whereas in glimepiride group it was reduced 7.72mmol/L to 7.37mmol/L. Though the reduction of both HbA1c% and fasting blood sugar was suboptimal, but the reduction in pioglitazone group was significant (p<.05) and in glimepiride group was near to significant (P=0.067 and P=0.052 respectively) ( Table-I ). The mean change of HbA1c% was 0.85% in pioglitazone group and 0.26% in glimepiride group. The change in pioglitazone group was significant (P<0.05).
In this study there was change of serum mean hs-CRP level from 1.13 mg/L to 0.76 mg/L in pioglitazone group after 12 weeks of pioglitazone (30 gm) intervention and in glimepiride group who did not receive pioglitazone, the change of serum mean hs-CRP level was 0.96 mg/L to 0.94 mg/L after 12 weeks (Table-II ). This change in hs-CRP in pioglitazone group in comparison to glimepiride group is statistically significant (p>0.05).
Haffiner SM et al. in 2002 showed that the decline in CRP was 0.155 mg/dl in placebo group, 0.52 mg/dl in rosiglitazone 8 mg/day group. 7 The decline in CRP in placebo group was not significant but in rosiglitazone group was significant (P<0.05). Pfutzner A et al. showed in 2005 that a significant reduction of hs-CRP was seen after six months of therapy in pioglitoazone (-0.10±2.25 mg/dl, -29%, endpoint vs, baseline, p<0.01) while no such change could be seen during glimepiride treatment (0.2±4.0 mg/dl, -4%, p=not significant). 8 Mohanty and his colleagues reported a decrease in CRP of 30% when 11 obese patients without diabetes were treated with rosiglitazone 4 mg daily for 6 weeks. 9 These studies are consistent with our studies regarding the reduction of serum hs-CRP level of type 2 diabetic patients by the use of thiazolidinediones. So we can conclude that thiazolidinediones can be used for type 2 diabetic patients to reduce the diabetes and its related cardiovascular complications.
In our study there was no change in high density lipoprotein (HDL) cholesterol (39 mg/dl) before and after drug in glimepiride group and 40 mg/dl before and after drug in pioglitazone group. Total cholesterol raises mildly in glimepiride group (200 mg/dl to 209 mg/dl) after treatment with glimepiride but mildly decreased in pioglitazone group after treatment with pioglitazone (211 mg/dl to 208 mg/dl). Similar mild elevation in low density lipoprotein LDL cholesterol in glimepiride group (110 mg/dl to 117 mg/dl) and mild decrease in pioglitazone group after pioglitazone intervention (115 mg/dl to 112 mg/dl). Triglyceride level was rather slightly raised in pioglitazone group after pioglitazone intervention (210 mg/dl to 212 mg/dl) and mildly reduced in glimepiride group (219 mg/dl to 216 mg/dl) ( Table-III ). In a word there was no significant change in lipid profile after drug intervention in our study (p>0.05).
Ghazzi and his collagues demonstrated that the troglitazone therapy decreased triglyceride level while increased high density lipoprotein (HDL) level in patients with type 2 diabetes. 10 Similarly , treatment with 15, 30 and 45 mg of pioglitazone significantly decreased triglyceride compared with placebo (P<0.05) and significantly increased HDL cholesterol (P<0.05). 11 Rosiglitazone therapy also decreased triglyceride in patients with a high baseline level increased HDL cholesterol by 10% to 30%. 12 Ours results regarding effect of pioglitazone on the lipids is not fully consistent with the above studies. This may be due to the short durations of drug application (12 weeks only) as well as use of low dose of pioglitazone (30mg), or may be due to dietary habit of our diabetic patients, because carbohydrates (rice and bread) are the main foods of our patients.
In our study population none developed pedal oedema, pulmonary oedema and congestive heart failure or became anaemic, but there was little weight gain in pioglitazone group who received pioglitazone (30 mg) for 12 weeks. There was no change in weight in glimepiride group after 12 weeks of treatment with glimepiride (Table-IV ). In pioglitazone group mean increase in weight in male was 1 kg and in female it was 0.9 kg only and this increase in weight was not significant (P>0.05) in comparison to glimepiride group. Haffiner SM et al. showed that after 26 weeks of rosiglitazone treatment, patients in the placebo group lost 1.1 kg as opposed to 1.8 kg increase in the rosiglitazone 4 mg/day group and 3.5 kg increase in rosiglitazone 8 mg/day group (P<0.001 compared with baseline). Our study is consistent with these studies. 7
Conclusion
This small study may not reflect the exact situation of the fact in the community but its proximity to the reality can not Comparison between Effect of Glimepiride and Pioglitazone on the C-Reactive Protein Level JM Vol. 12, No. 1 be underestimated. The reduction of hs-CRP level in pioglitazone group was significant in comparison to glimepiride group (0.39 mg/L Vs 0.02 mg/L). Other effects of pioglitazone, like hypoglycemic effect and effect on lipid profile were also satisfactory and no significant adverse effect was demonstrated. As diabetes is a growing epidemic globally, the morbidity and mortality of diabetes is also gradually increasing. This morbidity and mortality is mainly due to vascular complications of type-2 diabetes (stroke, myocardial infarction). It is now proved that these vascular complications, especially macrovascular complications are due to induction of chronic inflammations resulting from insulin resistance which leads to atherosclerosis. So, to prevent these incidence thiazolidinediones (pioglitazone) may be used as early pharmacological therapy in type-2 diabetic patients.
